Intrepid Capital Management Lowered Bio Rad Labs Cl A (BIO) Stake; Tourbillon Capital Partners LP Has Lowered By $1.64 Million Its Baidu (Call) (BIDU) Position

August 23, 2017 - By Clifton Ray

Intrepid Capital Management Inc decreased Bio Rad Labs Inc Cl A (BIO) stake by 15.7% reported in 2016Q4 SEC filing. Intrepid Capital Management Inc sold 6,455 shares as Bio Rad Labs Inc Cl A (BIO)’s stock rose 13.43%. The Intrepid Capital Management Inc holds 34,649 shares with $6.32 million value, down from 41,104 last quarter. Bio Rad Labs Inc Cl A now has $6.43B valuation. The stock declined 1.30% or $2.86 reaching $217.65 per share. About 34,455 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 53.78% since August 23, 2016 and is uptrending. It has outperformed by 37.08% the S&P500.

Tourbillon Capital Partners Lp decreased Baidu Inc (Call) (BIDU) stake by 7.69% reported in 2016Q4 SEC filing. Tourbillon Capital Partners Lp sold 10,000 shares as Baidu Inc (Call) (BIDU)’s stock rose 1.94%. The Tourbillon Capital Partners Lp holds 120,000 shares with $19.73 million value, down from 130,000 last quarter. Baidu Inc (Call) now has $77.87B valuation. The stock declined 0.69% or $1.55 reaching $224.56 per share. About 710,427 shares traded. Baidu Inc (ADR) (NASDAQ:BIDU) has risen 12.02% since August 23, 2016 and is uptrending. It has underperformed by 4.68% the S&P500.

Investors sentiment increased to 1.17 in Q4 2016. Its up 0.09, from 1.08 in 2016Q3. It is positive, as 25 investors sold BIO shares while 73 reduced holdings. 39 funds opened positions while 76 raised stakes. 18.93 million shares or 3.35% more from 18.31 million shares in 2016Q3 were reported. California-based Gemmer Asset Mgmt has invested 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Tygh Mngmt has 29,896 shares for 1.37% of their portfolio. Winslow Asset Management has invested 1.07% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Vanguard Gp reported 0.02% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Blackrock Advisors Limited has invested 0% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Parkside Savings Bank Trust reported 53 shares or 0% of all its holdings. Franklin Inc reported 131,428 shares. Portolan Cap Mngmt Lc owns 79,009 shares for 1.94% of their portfolio. Lombard Odier Asset Mngmt (Switzerland) holds 0.81% in Bio-Rad Laboratories, Inc. (NYSE:BIO) or 17,500 shares. Gabelli Funds Llc, a New York-based fund reported 45,700 shares. Qs Invsts Ltd holds 0% or 7 shares in its portfolio. Bluecrest Mgmt owns 66,270 shares. Tudor Et Al owns 59,100 shares for 0.28% of their portfolio. M&T Fincl Bank invested in 3,184 shares. Ariel Invests Limited Company invested in 886,827 shares or 1.91% of the stock.

Since March 2, 2017, it had 1 insider purchase, and 6 sales for $2.95 million activity. The insider GOETZ JOHN sold $770,590. $881,300 worth of stock was sold by Magni Giovanni on Monday, March 6. The insider Crowley Michael sold $58,840. Hall Shannon sold $200,387 worth of stock. Another trade for 500 shares valued at $109,792 was bought by HINCKLEY GREGORY K.

Among 4 analysts covering Bio-Rad Laboratories (NYSE:BIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Rad Laboratories had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Thursday, July 13 with “Buy”. The firm earned “Buy” rating on Wednesday, June 28 by Deutsche Bank. Jefferies maintained it with “Buy” rating and $225 target in Wednesday, September 7 report. Jefferies maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) on Friday, April 28 with “Buy” rating. As per Thursday, October 13, the company rating was initiated by CL King. The rating was maintained by Jefferies on Wednesday, April 12 with “Buy”. As per Thursday, June 8, the company rating was maintained by Jefferies.